100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R44CA210820
Award Date
12/8/16
Completion Date
5/31/23
Dollars Obligated
$10M
Overview
Activity
9
Transactions
9
Subawards
Similar Awards
Federal Agency
National Cancer Institute
Awardee
Curadel LLC (ZWWLNUMQH996)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Natick, MA 01760, USA
Update #1
Update #2
ZW800-1: THE 1ST ZWITTERIONIC NIR FLUOROPHORE FOR CANCER IMAGING & URETER MAPPING
Posted 12/8/16
5
1
2
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
ZW800-1: THE 1ST ZWITTERIONIC NIR FLUOROPHORE FOR CANCER IMAGING & URETER MAPPING - IMAGE-GUIDED SURGERY USING INVISIBLE NEAR-INFRARED (NIR) FLUORESCENT LIGHT IS HERE TO STAY. MULTIPLE COMMERCIAL IMAGING SYSTEMS FROM STRYKER, OLYMPUS, MEDTRONIC, AND INTUITIVE SURGICAL ARE NOW AVAILABLE FOR HUMAN SURGERY. HOWEVER, ONLY INNOVATIVE NIR FLUOROPHORES WILL SOLVE MAJOR CLINICAL PROBLEMS. CURADEL HAS INVENTED A NOVEL FAMILY OF NIR FLUOROPHORES TERMED "ZWITTERIONIC," OR MORE PRECISELY, GEOMETRICALLY-BALANCED, ELECTRICALLY-NEUTRAL, POLYIONIC POLYMETHINE INDOCYANINES. ZWITTERIONIC NIR FLUOROPHORES, SUCH AS ZW800-1, EXHIBIT ULTRALOW NON-SPECIFIC BINDING AND UPTAKE IN NORMAL TISSUES AND ORGANS, AS WELL AS 100% RENAL CLEARANCE AND ELIMINATION INTO URINE. WITHIN 1-10 MIN AFTER A LOW ( 2.5 MG) DOSE INTRAVENOUS (IV) INJECTION, THE URETERS BECOME HIGHLY NIR FLUORESCENT FOR UP TO 3.6 H, THUS PROVIDING SURGEONS WITH THE ABILITY TO AVOID THEM DURING ALL ABDOMINOPELVIC CANCER SURGERIES. IN FACT, IN MOST CASES ZW800-1 ELIMINATES THE NEED TO SURGICALLY DISSECT, IDENTIFY, AND ISOLATE THE URETERS ALTOGETHER, SAVING OVER 20 MIN OF OR TIME, REDUCING ANESTHESIA TIME, AND REDUCING THE RISK OF COMPLICATIONS, SUCH AS ADHESIONS. CURRENTLY, URETER DAMAGE IS QUITE COMMON IN CANCER SURGERY AND LEADS TO ENORMOUS COST ($1.35B ANNUALLY IN THE USA ALONE) AND HIGH PATIENT MORBIDITY. BECAUSE OF ITS CLINICAL POTENTIAL, ZW800-1 WAS DEEMED A HIGH VALUE ASSET BY THE NCI'S EXPERIMENTAL THERAPEUTICS (NEXT) PROGRAM AND WAS ACCEPTED INTO THE FIRST-IN-HUMAN TRACT. TWO-SPECIES TOXICITY, AS WELL AS GENOTOXICITY AND MUTAGENICITY, WERE EXTRAORDINARILY LOW. CURADEL USED A DIRECT-TO-PHASE II SBIR GRANT (NCI 5R44-CA-210820-02) TO SCALE-UP CGMP PRODUCTION, QUALIFY IMPURITIES, AND OPTIMIZE ASEPTIC FILL-FINISH, WHILE COLLABORATORS IN EUROPE PERFORMED A PHASE 1 TRIAL ON HUMAN VOLUNTEERS AND A PHASE 2 TRIAL ON PATIENTS UNDERGOING ABDOMINOPELVIC SURGERY FOR CANCER RESECTION. THE RESULTS OF THE PHASE 1 AND 2 TRIALS PRESENTED HEREIN ARE EXCEPTIONAL AND VALIDATE OUR HYPOTHESIS THAT ZW800-1 IS AN IDEAL CONTRAST AGENT FOR URETER MAPPING. A SINGLE LOW DOSE PERMITTED URETER MAPPING FOR HOURS ON FLARE, OLYMPUS, AND DA VINCI NIR FLUORESCENCE IMAGING SYSTEMS, AND COULD BE REPEATED IF NEEDED FOR LONGER CASES. ZW800-1 IS NOW POISED TO COMPLETE THE REMAINING STEPS OF MARKET APPROVAL WHERE WE ANTICIPATE WIDESPREAD ADOPTION IN ABDOMINOPELVIC CANCER SURGERY. INNOVATIVE ASPECTS OF OUR APPLICATION INCLUDE A CGMP SYNTHESIS AND ASEPTIC FILL-FINISH STRATEGY THAT DOES NOT REQUIRE EXCIPIENTS OR OTHER ADDITIVES YET RESULTS IN A FINAL DRUG PRODUCT WITH > 5 YEARS OF STABILITY, AND A COMMERCIALIZATION PLAN THAT REQUIRES ONLY $8M TO GET TO NDA SUBMISSION YET RESULTS IN A COMMERCIAL PRODUCT WITH >93% GROSS MARGIN AND A $100M+ ANNUAL MARKET. OUR COMPETITIVE POSITION IS ALSO UNUSUALLY STRONG BECAUSE OF ISSUED PATENT CLAIMS FOR ZW800-1 IN USA, EUROPE, JAPAN, AND AUSTRALIA, AND UNIQUE PHARMACOKINETICS THAT NO OTHER COMPETING NIR FLUOROPHORE CAN MATCH. OUR LONG-TERM GOAL IS TO SOLVE THE PROBLEM OF URETER MAPPING DURING CANCER SURGERY ONCE AND FOR ALL.
($500)
1/29/24
Not listed
ZW800-1: THE 1ST ZWITTERIONIC NIR FLUOROPHORE FOR CANCER IMAGING & URETER MAPPING - IMAGE-GUIDED SURGERY USING INVISIBLE NEAR-INFRARED (NIR) FLUORESCENT LIGHT IS HERE TO STAY. MULTIPLE COMMERCIAL IMAGING SYSTEMS FROM STRYKER, OLYMPUS, MEDTRONIC, AND INTUITIVE SURGICAL ARE NOW AVAILABLE FOR HUMAN SURGERY. HOWEVER, ONLY INNOVATIVE NIR FLUOROPHORES WILL SOLVE MAJOR CLINICAL PROBLEMS. CURADEL HAS INVENTED A NOVEL FAMILY OF NIR FLUOROPHORES TERMED "ZWITTERIONIC," OR MORE PRECISELY, GEOMETRICALLY-BALANCED, ELECTRICALLY-NEUTRAL, POLYIONIC POLYMETHINE INDOCYANINES. ZWITTERIONIC NIR FLUOROPHORES, SUCH AS ZW800-1, EXHIBIT ULTRALOW NON-SPECIFIC BINDING AND UPTAKE IN NORMAL TISSUES AND ORGANS, AS WELL AS 100% RENAL CLEARANCE AND ELIMINATION INTO URINE. WITHIN 1-10 MIN AFTER A LOW (= 2.5 MG) DOSE INTRAVENOUS (IV) INJECTION, THE URETERS BECOME HIGHLY NIR FLUORESCENT FOR UP TO 3.6 H, THUS PROVIDING SURGEONS WITH THE ABILITY TO AVOID THEM DURING ALL ABDOMINOPELVIC CANCER SURGERIES. IN FACT, IN MOST CASES ZW800-1 ELIMINATES THE NEED TO SURGICALLY DISSECT, IDENTIFY, AND ISOLATE THE URETERS ALTOGETHER, SAVING OVER 20 MIN OF OR TIME, REDUCING ANESTHESIA TIME, AND REDUCING THE RISK OF COMPLICATIONS, SUCH AS ADHESIONS. CURRENTLY, URETER DAMAGE IS QUITE COMMON IN CANCER SURGERY AND LEADS TO ENORMOUS COST ($1.35B ANNUALLY IN THE USA ALONE) AND HIGH PATIENT MORBIDITY. BECAUSE OF ITS CLINICAL POTENTIAL, ZW800-1 WAS DEEMED A HIGH VALUE ASSET BY THE NCI'S EXPERIMENTAL THERAPEUTICS (NEXT) PROGRAM AND WAS ACCEPTED INTO THE FIRST-IN-HUMAN TRACT. TWO-SPECIES TOXICITY, AS WELL AS GENOTOXICITY AND MUTAGENICITY, WERE EXTRAORDINARILY LOW. CURADEL USED A DIRECT-TO-PHASE II SBIR GRANT (NCI 5R44-CA-210820-02) TO SCALE-UP CGMP PRODUCTION, QUALIFY IMPURITIES, AND OPTIMIZE ASEPTIC FILL-FINISH, WHILE COLLABORATORS IN EUROPE PERFORMED A PHASE 1 TRIAL ON HUMAN VOLUNTEERS AND A PHASE 2 TRIAL ON PATIENTS UNDERGOING ABDOMINOPELVIC SURGERY FOR CANCER RESECTION. THE RESULTS OF THE PHASE 1 AND 2 TRIALS PRESENTED HEREIN ARE EXCEPTIONAL AND VALIDATE OUR HYPOTHESIS THAT ZW800-1 IS AN IDEAL CONTRAST AGENT FOR URETER MAPPING. A SINGLE LOW DOSE PERMITTED URETER MAPPING FOR HOURS ON FLARE, OLYMPUS, AND DA VINCI NIR FLUORESCENCE IMAGING SYSTEMS, AND COULD BE REPEATED IF NEEDED FOR LONGER CASES. ZW800-1 IS NOW POISED TO COMPLETE THE REMAINING STEPS OF MARKET APPROVAL WHERE WE ANTICIPATE WIDESPREAD ADOPTION IN ABDOMINOPELVIC CANCER SURGERY. INNOVATIVE ASPECTS OF OUR APPLICATION INCLUDE A CGMP SYNTHESIS AND ASEPTIC FILL-FINISH STRATEGY THAT DOES NOT REQUIRE EXCIPIENTS OR OTHER ADDITIVES YET RESULTS IN A FINAL DRUG PRODUCT WITH > 5 YEARS OF STABILITY, AND A COMMERCIALIZATION PLAN THAT REQUIRES ONLY $8M TO GET TO NDA SUBMISSION YET RESULTS IN A COMMERCIAL PRODUCT WITH >93% GROSS MARGIN AND A $100M+ ANNUAL MARKET. OUR COMPETITIVE POSITION IS ALSO UNUSUALLY STRONG BECAUSE OF ISSUED PATENT CLAIMS FOR ZW800-1 IN USA, EUROPE, JAPAN, AND AUSTRALIA, AND UNIQUE PHARMACOKINETICS THAT NO OTHER COMPETING NIR FLUOROPHORE CAN MATCH. OUR LONG-TERM GOAL IS TO SOLVE THE PROBLEM OF URETER MAPPING DURING CANCER SURGERY ONCE AND FOR ALL.
$808.0k
5/24/22
Not listed
ZW800-1: THE 1ST ZWITTERIONIC NIR FLUOROPHORE FOR CANCER IMAGING & URETER MAPPING - IMAGE-GUIDED SURGERY USING INVISIBLE NEAR-INFRARED (NIR) FLUORESCENT LIGHT IS HERE TO STAY. MULTIPLE COMMERCIAL IMAGING SYSTEMS FROM STRYKER, OLYMPUS, MEDTRONIC, AND INTUITIVE SURGICAL ARE NOW AVAILABLE FOR HUMAN SURGERY. HOWEVER, ONLY INNOVATIVE NIR FLUOROPHORES WILL SOLVE MAJOR CLINICAL PROBLEMS. CURADEL HAS INVENTED A NOVEL FAMILY OF NIR FLUOROPHORES TERMED "ZWITTERIONIC," OR MORE PRECISELY, GEOMETRICALLY-BALANCED, ELECTRICALLY-NEUTRAL, POLYIONIC POLYMETHINE INDOCYANINES. ZWITTERIONIC NIR FLUOROPHORES, SUCH AS ZW800-1, EXHIBIT ULTRALOW NON-SPECIFIC BINDING AND UPTAKE IN NORMAL TISSUES AND ORGANS, AS WELL AS 100% RENAL CLEARANCE AND ELIMINATION INTO URINE. WITHIN 1-10 MIN AFTER A LOW (= 2.5 MG) DOSE INTRAVENOUS (IV) INJECTION, THE URETERS BECOME HIGHLY NIR FLUORESCENT FOR UP TO 3.6 H, THUS PROVIDING SURGEONS WITH THE ABILITY TO AVOID THEM DURING ALL ABDOMINOPELVIC CANCER SURGERIES. IN FACT, IN MOST CASES ZW800-1 ELIMINATES THE NEED TO SURGICALLY DISSECT, IDENTIFY, AND ISOLATE THE URETERS ALTOGETHER, SAVING OVER 20 MIN OF OR TIME, REDUCING ANESTHESIA TIME, AND REDUCING THE RISK OF COMPLICATIONS, SUCH AS ADHESIONS. CURRENTLY, URETER DAMAGE IS QUITE COMMON IN CANCER SURGERY AND LEADS TO ENORMOUS COST ($1.35B ANNUALLY IN THE USA ALONE) AND HIGH PATIENT MORBIDITY. BECAUSE OF ITS CLINICAL POTENTIAL, ZW800-1 WAS DEEMED A HIGH VALUE ASSET BY THE NCI'S EXPERIMENTAL THERAPEUTICS (NEXT) PROGRAM AND WAS ACCEPTED INTO THE FIRST-IN-HUMAN TRACT. TWO-SPECIES TOXICITY, AS WELL AS GENOTOXICITY AND MUTAGENICITY, WERE EXTRAORDINARILY LOW. CURADEL USED A DIRECT-TO-PHASE II SBIR GRANT (NCI 5R44-CA-210820-02) TO SCALE-UP CGMP PRODUCTION, QUALIFY IMPURITIES, AND OPTIMIZE ASEPTIC FILL-FINISH, WHILE COLLABORATORS IN EUROPE PERFORMED A PHASE 1 TRIAL ON HUMAN VOLUNTEERS AND A PHASE 2 TRIAL ON PATIENTS UNDERGOING ABDOMINOPELVIC SURGERY FOR CANCER RESECTION. THE RESULTS OF THE PHASE 1 AND 2 TRIALS PRESENTED HEREIN ARE EXCEPTIONAL AND VALIDATE OUR HYPOTHESIS THAT ZW800-1 IS AN IDEAL CONTRAST AGENT FOR URETER MAPPING. A SINGLE LOW DOSE PERMITTED URETER MAPPING FOR HOURS ON FLARE, OLYMPUS, AND DA VINCI NIR FLUORESCENCE IMAGING SYSTEMS, AND COULD BE REPEATED IF NEEDED FOR LONGER CASES. ZW800-1 IS NOW POISED TO COMPLETE THE REMAINING STEPS OF MARKET APPROVAL WHERE WE ANTICIPATE WIDESPREAD ADOPTION IN ABDOMINOPELVIC CANCER SURGERY. INNOVATIVE ASPECTS OF OUR APPLICATION INCLUDE A CGMP SYNTHESIS AND ASEPTIC FILL-FINISH STRATEGY THAT DOES NOT REQUIRE EXCIPIENTS OR OTHER ADDITIVES YET RESULTS IN A FINAL DRUG PRODUCT WITH > 5 YEARS OF STABILITY, AND A COMMERCIALIZATION PLAN THAT REQUIRES ONLY $8M TO GET TO NDA SUBMISSION YET RESULTS IN A COMMERCIAL PRODUCT WITH >93% GROSS MARGIN AND A $100M+ ANNUAL MARKET. OUR COMPETITIVE POSITION IS ALSO UNUSUALLY STRONG BECAUSE OF ISSUED PATENT CLAIMS FOR ZW800-1 IN USA, EUROPE, JAPAN, AND AUSTRALIA, AND UNIQUE PHARMACOKINETICS THAT NO OTHER COMPETING NIR FLUOROPHORE CAN MATCH. OUR LONG-TERM GOAL IS TO SOLVE THE PROBLEM OF URETER MAPPING DURING CANCER SURGERY ONCE AND FOR ALL.
$808.0k
5/24/22
Not listed
ZW800-1: THE 1ST ZWITTERIONIC NIR FLUOROPHORE FOR CANCER IMAGING & URETER MAPPING - IMAGE-GUIDED SURGERY USING INVISIBLE NEAR-INFRARED (NIR) FLUORESCENT LIGHT IS HERE TO STAY. MULTIPLE COMMERCIAL IMAGING SYSTEMS FROM STRYKER, OLYMPUS, MEDTRONIC, AND INTUITIVE SURGICAL ARE NOW AVAILABLE FOR HUMAN SURGERY. HOWEVER, ONLY INNOVATIVE NIR FLUOROPHORES WILL SOLVE MAJOR CLINICAL PROBLEMS. CURADEL HAS INVENTED A NOVEL FAMILY OF NIR FLUOROPHORES TERMED "ZWITTERIONIC," OR MORE PRECISELY, GEOMETRICALLY-BALANCED, ELECTRICALLY-NEUTRAL, POLYIONIC POLYMETHINE INDOCYANINES. ZWITTERIONIC NIR FLUOROPHORES, SUCH AS ZW800-1, EXHIBIT ULTRALOW NON-SPECIFIC BINDING AND UPTAKE IN NORMAL TISSUES AND ORGANS, AS WELL AS 100% RENAL CLEARANCE AND ELIMINATION INTO URINE. WITHIN 1-10 MIN AFTER A LOW (= 2.5 MG) DOSE INTRAVENOUS (IV) INJECTION, THE URETERS BECOME HIGHLY NIR FLUORESCENT FOR UP TO 3.6 H, THUS PROVIDING SURGEONS WITH THE ABILITY TO AVOID THEM DURING ALL ABDOMINOPELVIC CANCER SURGERIES. IN FACT, IN MOST CASES ZW800-1 ELIMINATES THE NEED TO SURGICALLY DISSECT, IDENTIFY, AND ISOLATE THE URETERS ALTOGETHER, SAVING OVER 20 MIN OF OR TIME, REDUCING ANESTHESIA TIME, AND REDUCING THE RISK OF COMPLICATIONS, SUCH AS ADHESIONS. CURRENTLY, URETER DAMAGE IS QUITE COMMON IN CANCER SURGERY AND LEADS TO ENORMOUS COST ($1.35B ANNUALLY IN THE USA ALONE) AND HIGH PATIENT MORBIDITY. BECAUSE OF ITS CLINICAL POTENTIAL, ZW800-1 WAS DEEMED A HIGH VALUE ASSET BY THE NCI'S EXPERIMENTAL THERAPEUTICS (NEXT) PROGRAM AND WAS ACCEPTED INTO THE FIRST-IN-HUMAN TRACT. TWO-SPECIES TOXICITY, AS WELL AS GENOTOXICITY AND MUTAGENICITY, WERE EXTRAORDINARILY LOW. CURADEL USED A DIRECT-TO-PHASE II SBIR GRANT (NCI 5R44-CA-210820-02) TO SCALE-UP CGMP PRODUCTION, QUALIFY IMPURITIES, AND OPTIMIZE ASEPTIC FILL-FINISH, WHILE COLLABORATORS IN EUROPE PERFORMED A PHASE 1 TRIAL ON HUMAN VOLUNTEERS AND A PHASE 2 TRIAL ON PATIENTS UNDERGOING ABDOMINOPELVIC SURGERY FOR CANCER RESECTION. THE RESULTS OF THE PHASE 1 AND 2 TRIALS PRESENTED HEREIN ARE EXCEPTIONAL AND VALIDATE OUR HYPOTHESIS THAT ZW800-1 IS AN IDEAL CONTRAST AGENT FOR URETER MAPPING. A SINGLE LOW DOSE PERMITTED URETER MAPPING FOR HOURS ON FLARE, OLYMPUS, AND DA VINCI NIR FLUORESCENCE IMAGING SYSTEMS, AND COULD BE REPEATED IF NEEDED FOR LONGER CASES. ZW800-1 IS NOW POISED TO COMPLETE THE REMAINING STEPS OF MARKET APPROVAL WHERE WE ANTICIPATE WIDESPREAD ADOPTION IN ABDOMINOPELVIC CANCER SURGERY. INNOVATIVE ASPECTS OF OUR APPLICATION INCLUDE A CGMP SYNTHESIS AND ASEPTIC FILL-FINISH STRATEGY THAT DOES NOT REQUIRE EXCIPIENTS OR OTHER ADDITIVES YET RESULTS IN A FINAL DRUG PRODUCT WITH > 5 YEARS OF STABILITY, AND A COMMERCIALIZATION PLAN THAT REQUIRES ONLY $8M TO GET TO NDA SUBMISSION YET RESULTS IN A COMMERCIAL PRODUCT WITH >93% GROSS MARGIN AND A $100M+ ANNUAL MARKET. OUR COMPETITIVE POSITION IS ALSO UNUSUALLY STRONG BECAUSE OF ISSUED PATENT CLAIMS FOR ZW800-1 IN USA, EUROPE, JAPAN, AND AUSTRALIA, AND UNIQUE PHARMACOKINETICS THAT NO OTHER COMPETING NIR FLUOROPHORE CAN MATCH. OUR LONG-TERM GOAL IS TO SOLVE THE PROBLEM OF URETER MAPPING DURING CANCER SURGERY ONCE AND FOR ALL.
$1.6m
5/21/21
Not listed
ZW800-1: THE 1ST ZWITTERIONIC NIR FLUOROPHORE FOR CANCER IMAGING & URETER MAPPING - IMAGE-GUIDED SURGERY USING INVISIBLE NEAR-INFRARED (NIR) FLUORESCENT LIGHT IS HERE TO STAY. MULTIPLE COMMERCIAL IMAGING SYSTEMS FROM STRYKER, OLYMPUS, MEDTRONIC, AND INTUITIVE SURGICAL ARE NOW AVAILABLE FOR HUMAN SURGERY. HOWEVER, ONLY INNOVATIVE NIR FLUOROPHORES WILL SOLVE MAJOR CLINICAL PROBLEMS. CURADEL HAS INVENTED A NOVEL FAMILY OF NIR FLUOROPHORES TERMED "ZWITTERIONIC," OR MORE PRECISELY, GEOMETRICALLY-BALANCED, ELECTRICALLY-NEUTRAL, POLYIONIC POLYMETHINE INDOCYANINES. ZWITTERIONIC NIR FLUOROPHORES, SUCH AS ZW800-1, EXHIBIT ULTRALOW NON-SPECIFIC BINDING AND UPTAKE IN NORMAL TISSUES AND ORGANS, AS WELL AS 100% RENAL CLEARANCE AND ELIMINATION INTO URINE. WITHIN 1-10 MIN AFTER A LOW (= 2.5 MG) DOSE INTRAVENOUS (IV) INJECTION, THE URETERS BECOME HIGHLY NIR FLUORESCENT FOR UP TO 3.6 H, THUS PROVIDING SURGEONS WITH THE ABILITY TO AVOID THEM DURING ALL ABDOMINOPELVIC CANCER SURGERIES. IN FACT, IN MOST CASES ZW800-1 ELIMINATES THE NEED TO SURGICALLY DISSECT, IDENTIFY, AND ISOLATE THE URETERS ALTOGETHER, SAVING OVER 20 MIN OF OR TIME, REDUCING ANESTHESIA TIME, AND REDUCING THE RISK OF COMPLICATIONS, SUCH AS ADHESIONS. CURRENTLY, URETER DAMAGE IS QUITE COMMON IN CANCER SURGERY AND LEADS TO ENORMOUS COST ($1.35B ANNUALLY IN THE USA ALONE) AND HIGH PATIENT MORBIDITY. BECAUSE OF ITS CLINICAL POTENTIAL, ZW800-1 WAS DEEMED A HIGH VALUE ASSET BY THE NCI'S EXPERIMENTAL THERAPEUTICS (NEXT) PROGRAM AND WAS ACCEPTED INTO THE FIRST-IN-HUMAN TRACT. TWO-SPECIES TOXICITY, AS WELL AS GENOTOXICITY AND MUTAGENICITY, WERE EXTRAORDINARILY LOW. CURADEL USED A DIRECT-TO-PHASE II SBIR GRANT (NCI 5R44-CA-210820-02) TO SCALE-UP CGMP PRODUCTION, QUALIFY IMPURITIES, AND OPTIMIZE ASEPTIC FILL-FINISH, WHILE COLLABORATORS IN EUROPE PERFORMED A PHASE 1 TRIAL ON HUMAN VOLUNTEERS AND A PHASE 2 TRIAL ON PATIENTS UNDERGOING ABDOMINOPELVIC SURGERY FOR CANCER RESECTION. THE RESULTS OF THE PHASE 1 AND 2 TRIALS PRESENTED HEREIN ARE EXCEPTIONAL AND VALIDATE OUR HYPOTHESIS THAT ZW800-1 IS AN IDEAL CONTRAST AGENT FOR URETER MAPPING. A SINGLE LOW DOSE PERMITTED URETER MAPPING FOR HOURS ON FLARE, OLYMPUS, AND DA VINCI NIR FLUORESCENCE IMAGING SYSTEMS, AND COULD BE REPEATED IF NEEDED FOR LONGER CASES. ZW800-1 IS NOW POISED TO COMPLETE THE REMAINING STEPS OF MARKET APPROVAL WHERE WE ANTICIPATE WIDESPREAD ADOPTION IN ABDOMINOPELVIC CANCER SURGERY. INNOVATIVE ASPECTS OF OUR APPLICATION INCLUDE A CGMP SYNTHESIS AND ASEPTIC FILL-FINISH STRATEGY THAT DOES NOT REQUIRE EXCIPIENTS OR OTHER ADDITIVES YET RESULTS IN A FINAL DRUG PRODUCT WITH > 5 YEARS OF STABILITY, AND A COMMERCIALIZATION PLAN THAT REQUIRES ONLY $8M TO GET TO NDA SUBMISSION YET RESULTS IN A COMMERCIAL PRODUCT WITH >93% GROSS MARGIN AND A $100M+ ANNUAL MARKET. OUR COMPETITIVE POSITION IS ALSO UNUSUALLY STRONG BECAUSE OF ISSUED PATENT CLAIMS FOR ZW800-1 IN USA, EUROPE, JAPAN, AND AUSTRALIA, AND UNIQUE PHARMACOKINETICS THAT NO OTHER COMPETING NIR FLUOROPHORE CAN MATCH. OUR LONG-TERM GOAL IS TO SOLVE THE PROBLEM OF URETER MAPPING DURING CANCER SURGERY ONCE AND FOR ALL.
$1.6m
5/21/21